Eight FFPE tumor samples were evaluated from patients who had been diagnosed with HER2+ breast cancer and treated with two or more cycles of neoadjuvant trastuzumab prior to definitive surgery in order to assess the immune environment of HER2+ breast tumors post-trastuzumab treatment. The gene discussed is ERBB2; the disease is neoplasm.